---
title: Surgery to reduce protein buildup
nct_id: NCT06852352
phase: NA
status: RECRUITING
sponsor: "Zhejiang Provincial People's Hospital"
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06852352"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06852352"
last_fetched: "2026-05-10T14:06:22.816Z"
source: "Parkinson's Pathways (curated)"
---
# Surgery to reduce protein buildup

**Goal (in five words):** Surgery to reduce protein buildup

**Official Title:** A Prospective, Single-center, Single-arm, Exploratory, 24-Month Study to Confirm Efficacy of Modified Deep Cervical Lymphovenous Anastomosis (LVA) in Subjects With Alzheimer's Disease/ Parkinson's Disease

**Trial ID:** [NCT06852352](https://clinicaltrials.gov/study/NCT06852352)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Zhejiang Provincial People's Hospital
- **Target Enrollment:** 160 participants
- **Start Date:** 2025-02-28
- **Completion Date:** 2027-06-30
- **Conditions:** Alzheimer Disease, Parkinson Disease
- **Interventions:** Modified deep cervical Lymphatic-Venous Anastomosis
- **Intervention Types:** PROCEDURE

## Summary For Families

Aimed at improving brain waste clearance in Alzheimer's and Parkinson's, the trial tests whether surgically connecting deep cervical lymphatic vessels into nearby veins can reduce buildup of proteins like amyloid and alpha-synuclein and slow symptom progression over 24 months. The procedure, a modified deep cervical lymphatic-venous anastomosis, creates a new drainage route so cerebrospinal and interstitial fluid can leave the brain more efficiently, and it would be used alongside, not instead of, standard medications. They are looking for adults in two groups: people with Alzheimer's aged 50 to 75 who have positive amyloid PET scans, and people with Parkinson's aged 50 to 80 with Hoehn and Yahr stage I to IV and at least a couple years of stable symptoms. Candidates must be able to consent and be medically fit for MRI, PET, lumbar puncture, and surgery, and people with serious medical, bleeding, or uncontrolled psychiatric conditions are excluded.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

Alzheimer's disease:

1. Male or female, the age ranged from 50 to 75 years old
2. Informed consent signed and dated by patient or legal representative
3. Patients diagnosed principally with mild cognitive impairment or dementia caused by Alzheimer's disease
4. Positive result of Amyloid PET imaging (Centiloids ≥37)
5. HAMD score ≤17
6. Hachinski score ≤4 Patients who meet ASA (American Society of Anesthesiologists) grade I-III criteria

Parkinson's disease:

1. Male or female, the age ranged from 50 to 80 years old
2. Informed consent signed and dated by patient or legal representative
3. Patients diagnosed with Parkinson's disease or probable Parkinson's disease according to the Clinical Diagnostic Criteria for Parkinson's Disease in China (2016) or MDS
4. Stage I-IV patients according to Hoehn and Yahr Scale
5. Patients documented history of Parkinson's disease for more than 2-5 years to ensure clinical stability of symptoms and exclude the possibility of early misdiagnosis of other conditions

Exclusion Criteria:

1. Contraindications for MRI, ICG angiography, or PET scanning
2. Contraindications for lumbar puncture
3. Functional impairment of vital organs (cardiac, pulmonary, renal, hepatic), including reduced left ventricular ejection fraction, prolonged QT interval, severe pulmonary diseases, and severe hepatic/renal insufficiency
4. MRI results suggesting intracranial active/acute pathologies, including infections, space-occupying lesions, major hemorrhages, or ≥4 lobar microhemorrhages;
5. Conditions predisposing to increased intracranial hemorrhage risk, such as hematological disorders, hemorrhagic/coagulation disorders;
6. Poorly controlled thyroid dysfunction;
7. Cerebrovascular or systemic vasculopathy;
8. Severe cardiac disease or hemodynamic instability;
9. Uncontrolled severe hypertension;
10. Substance use disorders (including illicit drugs, anesthetics, and alcohol dependence);
11. Active severe infections, including HIV positivity and acute critical infections;
12. Severe psychiatric disorders or significant suicide risk;
13. Chronic hypnotic use (more than twice weekly for over one month);
14. History of untreated/uncured malignancies;
15. Participation in other interventional clinical trials within preceding 3 months;
16. Poor compliance with inability/unwillingness to complete scheduled postoperative follow-ups;
17. Other investigator-determined contraindications for trial participation.
```

## Locations (1)

- Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China _(30.2936, 120.1614)_
  - Youmao Zheng, MM — (CONTACT) — +86-571-85335800 — Zhengym6228@gmail.com

## Central Contacts

- Youmao Zheng — (CONTACT) — +86-571-85335800 — Zhengym6228@gmail.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06852352*  
*HTML version: https://parkinsonspathways.com/trial/NCT06852352*  
*Source data: https://clinicaltrials.gov/study/NCT06852352*